Minutes of meeting at BPL on 15/12/1982, with annotations. The agenda of the meeting is the implications for the Haemophilia and Blood Transfusion Services of Commercial Introduction of Hepatitis-Safe Factor VIII and IX. Topics discussed include commercial consideration and impact of this product; UK options in production; current commercial approach to UK users; UK options in production; efficacy and safety of HSVIII and HSIX; and proposals which include the creation of a formal basis for controlled clinical trial of alleged hepatitis safe products.